Chris Mirabelli (PhD) has served as the Chairman of the Board of Directors of Leap Therapeutics (LPTX) since 2016 and has also served as the President and Chief Executive Officer since the company’s inception in 2011. Dr. Mirabelli has been a Managing Director of HealthCare Ventures LLC since 2000. From December 1999 to May 2000, Dr. Mirabelli served as President of Pharmaceutical Research and Development and as a member of the Board of Directors of Millennium Pharmaceuticals following its merger with LeukoSite, where Dr. Mirabelli had been serving as President, Chief Executive Officer and Chairman of the Board of Directors since its inception in 1993. He was a cofounder of Ionis Pharmaceuticals, Inc. (IONS), where he held several positions, including Senior Vice President of Research, from 1989 until 1993. Dr. Mirabelli started his career at SmithKline and French Laboratories (now part of GlaxoSmithKline Plc) in the R&D Division. He is a member of the board of advisors of the Blavatnik Biomedical Accelerator Fund at Harvard Medical School and the Boston Biomedical Innovation Center. Dr. Mirabelli is a member of the Board of Trustees of Guilford College. He received his Ph.D. in Molecular Pharmacology from Baylor College of Medicine and a B.S. in Biology from State University of New York at Fredonia.